Nisa Investment Advisors
PRTK

Nisa Investment Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Nisa Investment Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-980
Closed -$5K – 2380
2020
Q3 		$5K Hold
980
– – ﹤0.01% 2202
2020
Q2 		$5K Hold
980
– – ﹤0.01% 2014
2020
Q1 		$3K Buy
+980
New +$3.62K ﹤0.01% 2030

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nisa Investment Advisors's PRTK Position: Q4 2020 in Review

Nisa Investment Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2020, closing a stake of 980 shares — an estimated $5K sold.

Nisa Investment Advisors first reported a position in PRTK in Q1 2020 and held it in 3 quarters. The position peaked at $5K in Q3 2020. 108 funds tracked by Wall St. Rank hold PRTK as of Q4 2020.

  • Nisa Investment Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Nisa Investment Advisors sold 980 Paratek Pharmaceuticals, Inc. shares in Q4 2020, an estimated $5K.
  • Nisa Investment Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2020 and held it in 3 quarters.
  • Nisa Investment Advisors's Paratek Pharmaceuticals, Inc. position peaked at $5K in Q3 2020.
  • 108 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2020.

Based on Nisa Investment Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.